Elevated expression of inhibin α in prostate cancer

Gail Petuna Risbridger, A Shibata, K L Ferguson, T A Stamey, J E McNeal, D M Peehl

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)


Purpose: Less than 50% of men who undergo radical prostatectomy for prostate cancer are cured of disease. We evaluate tumor expression of inhibin α, a putative tumor suppressor, and the related protein, follistatin, to determine whether expression correlated with failure to be cured by surgery. Materials and Methods: Tissues were selected from an archival collection of 379 prostatectomy specimens from men with followup of at least 5 years after surgery. Since previous studies showed that such men with only Gleason grade 3 cancer had a greater than 95% chance of no biochemical recurrence (increase in serum prostate specific antigen), our investigation was confined to 174 men with 2% or greater grade 4/5 cancer. These men had an intermediate rate of 'failure, providing an opportunity to analyze the potential contribution of inhibin α or follistatin to progression. Intensity of immunohistochemical labeling for inhibin α and follistatin in each cancer was compared with that in normal glands within the same tissue section. Results: The majority of cases showed more intense expression of inhibin α in cancer than in normal glands. Those individuals whose cancers had the most elevated expression of inhibin α had a higher risk of recurrence, although this association was not statistically significant. Follistatin was expressed equivalently in normal and cancer cells in the majority of cases and did not correlate with recurrence. Conclusions: Our finding that inhibin α is frequently overexpressed in high grade prostate cancer suggests that the role of inhibin α as a tumor suppressor needs to be reevaluated. Furthermore, assessment of inhibin α as a serum marker of prostate cancer, as used to diagnose ovarian cancer, may be warranted.

Original languageEnglish
Pages (from-to)192-196
Number of pages5
JournalJournal of Urology
Issue number1
Publication statusPublished - Jan 2004


  • Follistatin
  • Inhibins
  • Prognosis
  • Prostatic neoplasms

Cite this